Sagimet Biosciences Inc. (SGMT)
Sagimet Biosciences Inc. (SGMT) from its SEC filings: 2023 revenue $2.0 million, net margin -1394%, free cash flow -$23.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2023) | $2.0 million |
| Net income | -$27.9 million |
| Net margin | -1393.8% |
| Free cash flow | -$23.8 million |
| Diluted EPS | $-2.66 |
| Cash | $165.9 million |
| Share count, 1 year | +44% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.